|
private:scigenltd.singapore-2
|
1432335
|
May 31st, 2019 12:00AM
|
SciGen Ltd., Singapore
|
354
|
20.00
|
Open
|
Biotechnology
|
May 31st, 2019 04:49PM
|
May 31st, 2019 04:49PM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
Open
|
BioPharmaceuticals
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 17th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 16th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 15th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 14th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 13th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 12th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 11th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 10th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|
|
private:scigenltd.singapore-2
|
1432335
|
Feb 9th, 2018 12:00AM
|
SciGen Ltd., Singapore
|
209
|
16.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin, rhuman GCSF, rhuman EPO, rhuman interferon alfa, and a third generation (mammalian cell culture derived) hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development, and are in the process of securing health registration.
SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on bacteria (E.coli) and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.
|
|
|
|
|
|
|
|
|
|
SciGen Ltd., Singapore
|
|
|